Clement v. Solta Medical CA1/5

CourtCalifornia Court of Appeal
DecidedSeptember 16, 2014
DocketA139965
StatusUnpublished

This text of Clement v. Solta Medical CA1/5 (Clement v. Solta Medical CA1/5) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Clement v. Solta Medical CA1/5, (Cal. Ct. App. 2014).

Opinion

Filed 9/16/14 Clement v. Solta Medical CA1/5 NOT TO BE PUBLISHED IN OFFICIAL REPORTS California Rules of Court, rule 8.1115(a), prohibits courts and parties from citing or relying on opinions not certified for publication or ordered published, except as specified by rule 8.1115(b). This opinion has not been certified for publication or ordered published for purposes of rule 8.1115.

IN THE COURT OF APPEAL OF THE STATE OF CALIFORNIA

FIRST APPELLATE DISTRICT

DIVISION FIVE

RICHARD CLEMENT, as Representative, etc., Plaintiff and Appellant, A139965

v. (Alameda County SOLTA MEDICAL, INC., Super. Ct. No. RG12659048) Defendant and Respondent.

CLRS Technology Corporation (CLRS) developed CLARO, a dermatological product for acne treatment. It agreed to merge with a subsidiary of Solta Medical, Inc. (Solta), which had greater resources for marketing and sales. Under terms of an “Agreement and Plan of Merger” (Merger Agreement), former CLRS managers and shareholders would receive contingent payments, dependent upon on sales of CLARO. The Merger Agreement provided that Solta would have “complete discretion” over CLARO marketing and sales. Richard Clement, as the former CLRS shareholders’ representative, alleges Solta breached the contract and implied covenant of good faith and fair dealing by failing to market or sell CLARO, thus denying former shareholders additional compensation. The trial court sustained Solta’s demurrer, ruling that Solta did not breach the contract and the implied covenant could not alter the “complete discretion” granted to Solta in the contract. We affirm.

1 I. BACKGROUND In reviewing the trial court’s order sustaining the demurrer, we accept as true properly pleaded factual allegations of the complaint. (Kotlar v. Hartford Fire Ins. Co. (2000) 83 Cal.App.4th 1116, 1120.) Where a complaint incorporates terms of a contract, we consider those terms as part of the pleading. (Ibid.) Clement’s original and first amended complaints, each with the Merger Agreement attached, set forth the following facts. A. The Merger Agreement CLRS developed and produced dermatologic treatments based on intense pulsed light and heat including CLARO, which used intense pulsed light to treat acne. In October 2010, CLRS1 and Solta signed the Merger Agreement whereby a Solta subsidiary (Solta Temp, Inc.) merged into CLRS. CLRS became the surviving company but with the articles, bylaws, officers and board of directors of Solta Temp, Inc.2 Under the Merger Agreement, existing CLRS shareholders exchanged their CLRS stock for the right to receive certain “earnout” payments triggered by specified revenue or operating income milestones during “earnout periods” that spanned from January 1 to December 31, 2011. Two former CLRS managers, Richard Oberreiter and James Pereyra, also had the right to receive earnout payments if certain CLARO sales milestones were met. Payments to the shareholders and managers were to go through Clement as their designated representative. Solta had to certify the earnout payment amounts. Clement, as the former shareholders’ and managers’ representative, could dispute those amounts and if necessary submit the matter to binding arbitration before an arbitrating accountant.

1 The Merger Agreement was signed by a CLRS officer on behalf of CLRS and also by Clement as representative of CLRS shareholders. 2 Clement describes the merger as follows: “CLRS would merge with and into Solta and that Solta would be the surviving company of the merger.” Solta similarly describes the merger as “structured so that CLRS would be merged into a wholly-owned subsidiary of Solta.”

2 Solta further agreed to assume or satisfy all the outstanding liabilities of CLRS. The contingent earnout payments for CLRS shareholders would be reduced by the amounts paid to satisfy the CLRS indebtedness. Payouts at closing totaled $529,915.46 and included payments to Clement, Oberreiter, and Pereyra. A schedule of other company debt outstanding as of the closing date, and assumed by Solta, totaled $232,199.09, including additional amounts owed to Oberreiter and Pereyra. Principally at issue here are two provisions set forth in article V of the Merger Agreement, “ADDITIONAL AGREEMENTS.” Section 5.02,3 “Further Action; Reasonable Best Efforts,” provided in relevant part: “(b) Upon the terms and subject to the conditions of this [Merger] Agreement, each of the parties hereto shall use its reasonable best efforts to take, or cause to be taken, all appropriate action, and to do, or cause to be done, all things necessary, proper or advisable under applicable Laws to consummate and make effective the Merger. In case, at any time after the Effective Time, any further action is necessary or desirable to carry out the purposes of this Agreement, the proper officers and directors of each party to this [Merger] Agreement shall use their reasonable best efforts to take all such action.” (Italics added.) Section 5.06, “Company Products and Services from and after the Effective Time,” provided: “[Solta], [CLRS] and the Representative [(Clement)] acknowledge and agree that [Solta] shall have complete discretion in the ordinary course of its business over all matters relating to any [CLRS] Products and Services from and after the Effective Time, including, but not limited to, any matter relating to the development, testing, regulatory submission or regulatory approval, if applicable, manufacturing, marketing, sales, distribution, pricing, service or maintenance thereof.” (Italics added.) B. The Lawsuit In December 2012, Clement sued Solta in his capacity as representative of CLRS’s former shareholders. The original complaint alleged that in November and December 2010, Solta had prepared and approved formal budgets for the sale and

3 All undesignated section references are to the Merger Agreement.

3 marketing of CLARO, but “decided shortly after the start of the earnout periods that it would not support CLARO sales with marketing efforts during the earnout period.” Solta misrepresented its CLARO marketing plans to shareholders, stating in May 2011 that it was “ramping up production for CLARO” and that it had spent money on sales and marketing of CLARO in the first quarter of 2011. In fact, Solta “had not authorized the kind of investment in marketing [CLARO] that had been anticipated at the time of the acquisition of CLRS.” In August 2011, Solta falsely stated it expected CLARO and another project to “ ‘drive significant top line growth in the second half of the year.’ ” In fact, “Solta had already made a decision to substantially cease marketing efforts for CLARO during the earnout period.” In November 2011, Solta reported that it had determined as of September 30, 2011, that it would not make earnout payments because the revenue milestones would not be achieved, and that prediction became true. Clement alleged that Solta breached the Merger Agreement and implied covenant of good faith and fair dealing by “failing to use its reasonable best efforts to sell or market CLARO in breach of Section 5.02(b) . . . . Solta essentially ceased providing marketing and support for CLARO in early 2011.”4 Solta demurred to the complaint, arguing the theory of the complaint was “explicitly foreclosed by the unambiguous terms of the parties’ contract. . . . [The parties] agreed that Solta would have ‘complete discretion’ regarding ‘any matter relating to the development, testing, . . . manufacturing, marketing, sales [or] distribution’ of the product in question.” The trial court agreed the complaint failed to state a valid claim as pled. “[Clement’s] claims for breach of contract and breach of covenant are governed by the rules of contract interpretation discussed in Third Story Music Inc. v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Beatrice Co. v. State Board of Equalization
863 P.2d 683 (California Supreme Court, 1993)
April Enterprises, Inc. v. KTTV
147 Cal. App. 3d 805 (California Court of Appeal, 1983)
Aragon-Haas v. Family Security Insurance Services
231 Cal. App. 3d 232 (California Court of Appeal, 1991)
PMC, Inc. v. Porthole Yachts, Ltd.
76 Cal. Rptr. 2d 832 (California Court of Appeal, 1998)
Kotlar v. Hartford Fire Insurance
100 Cal. Rptr. 2d 246 (California Court of Appeal, 2000)
Cedars-Sinai Medical Center v. Shewry
41 Cal. Rptr. 3d 48 (California Court of Appeal, 2006)
Storek & Storek, Inc. v. Citicorp Real Estate, Inc.
122 Cal. Rptr. 2d 267 (California Court of Appeal, 2002)
Thrifty Payless, Inc. v. MARINERS MILE GATEWAY, LLC.
185 Cal. App. 4th 1050 (California Court of Appeal, 2010)
Davies v. Sallie Mae, Inc.
168 Cal. App. 4th 1086 (California Court of Appeal, 2008)
Wolf v. Walt Disney Pictures and Television
76 Cal. Rptr. 3d 585 (California Court of Appeal, 2008)
Pasadena Live, LLC v. City of Pasadena
8 Cal. Rptr. 3d 233 (California Court of Appeal, 2004)
New Hampshire Insurance v. Ridout Roofing Co.
80 Cal. Rptr. 2d 286 (California Court of Appeal, 1998)
EMPLOYERS REINSURANCE CO. v. Superior Court
74 Cal. Rptr. 3d 733 (California Court of Appeal, 2008)
Stearn v. County of San Bernardino
170 Cal. App. 4th 434 (California Court of Appeal, 2009)
Third Story Music, Inc. v. Waits
41 Cal. App. 4th 798 (California Court of Appeal, 1995)
Locke v. Warner Bros., Inc.
57 Cal. App. 4th 354 (California Court of Appeal, 1997)
Steiner v. Thexton
226 P.3d 359 (California Supreme Court, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
Clement v. Solta Medical CA1/5, Counsel Stack Legal Research, https://law.counselstack.com/opinion/clement-v-solta-medical-ca15-calctapp-2014.